Gene therapy has revolutionized the therapeutic landscape for hemophilia A and B, offering the prospect for persistent endogenous production of coagulation factors VIII and IX. Recent advances in adeno-associated virus (AAV)-mediated gene transfer, particularly the approvals of valoctocogene roxaparvovec (Roctavian) and etranacogene dezaparvovec (Hemgenix), mark significant milestones in hemophilia care. This mini-review synthesizes emerging clinical data from phase I–III trials published between 2022 and 2025, emphasizing efficacy, durability, and immunogenicity profiles of leading AAV-based therapies. Innovations in vector design, such as liverspecific promoters, codon-optimized constructs, and novel capsids (e.g., AAVhu37, AAVrh10, AAV-Spark100), have improved transgene expression and expanded eligibility. Despite notable success, challenges persist, including immune-mediated transaminitis, declining factor activity over time, particularly in hemophilia A, and limitations posed by preexisting neutralizing antibodies. Additionally, CRISPR-Cas9 and non-viral delivery systems are emerging as complementary strategies, potentially enhancing therapeutic precision and overcoming AAV-related barriers. The review also addresses the critical need for equitable access and scalable production models to ensure global availability of gene therapies. With ongoing innovation and multidisciplinary collaboration, gene therapy is poised to transition from experimental intervention to mainstream curative care in hemophilia and other hematologic diseases.

Emerging evidence reveals that interactions between the nervous system and tumor biology significantly influence cancer progression, metastasis, and therapeutic outcomes. Here, we elucidate the neurobiological mechanisms that underpin tumor development, highlighting the dynamic role of neural components within the tumor microenvironment (TME). Neural signals and structural adaptations in the TME stimulate tumorigenesis and enable cancer cell plasticity, mimicking neurodevelopmental processes. Astrocytic glial cells release neurotrophic factors that support metastatic colonization and enhance tumor cell survival. Notably, cancer cells can establish pseudo-tripartite synapses with neurons, promoting both proliferation and invasion. We explore the cancer-neural network interplay, emphasizing how axonal remodeling, circuit reorganization, and synaptic dysfunction not only drive tumor growth but also contribute to associated symptoms like seizures and chronic pain. Molecularly, mutations such as in PIK3CA and abnormalities in neurotransmitter signaling reveal how neurotumors communicate and adapt. Furthermore, metabolic stress responses from tumor cells can activate nociceptive neurons, sustaining malignant progression. Understanding these neurobiological interactions opens avenues for novel therapeutic strategies. Precision neuro-oncology may benefit from targeting neurotrophic signaling, synaptic pathways, and neuronal differentiation programs. Advances in biomarker research from neurotumors also contribute to improved diagnostic and prognostic tools. By integrating neuroscience insights into oncological frameworks, we propose a paradigm shift toward therapies that intercept the neural circuitry sustaining malignancies. This neuro-oncological approach holds promise in addressing aggressive cancer phenotypes and improving patient outcomes.

Colorectal cancer (CRC) continues to be a substantial cause of cancer-related fatality globally, necessitating improved diagnostic and therapeutic strategies. Exosomes, small extracellular vesicles that facilitate intercellular communication, as key mediators in CRC progression by transporting bioactive molecules, including non-coding RNAs (ncRNAs). These exosomal ncRNAs (exo-ncRNAs) participate in regulating gene expression, tumor proliferation, metastasis, chemoresistance, and immune escape. ExoncRNAs show distinct patterns in CRC, making them potential non-invasive indicators for early detection and prognosis. Additionally, the potential of exosome-based therapies, including engineered exosomal RNA delivery, offers new avenues for precision oncology. However, addressing challenges, such as standardization of exosome isolation methods, clinical validation, and mechanistic elucidation, is necessary before their full clinical implementation. This article offers a comprehensive synthesis of the recent knowledge of exo-ncRNAs in CRC, emphasizing their biological functions, molecular mechanisms, and translational potential in diagnostics and therapeutics. Future research integrating artificial intelligence and multi-omics approaches may further enhance the clinical utility of exo-ncRNAs, advancing precision medicine in CRC management.

Heavy metal (HM) exposure is a critical abiotic stress that adversely affects plant growth, development, and agricultural sustainability. While trace amounts of HMs are essential for cellular processes, excessive accumulation disrupts osmotic balance, induces oxidative stress, and leads to severe metabolic disorders. This leads to excessive production of reactive oxygen species (ROS) and methylglyoxal. These compounds cause lipid peroxidation, protein and enzyme damage, DNA disruption, and overall cellular dysfunction. To mitigate HM toxicity, plants employ a range of physiological, biochemical, and molecular defense mechanisms, including antioxidant enzyme systems, metal chelation, phytohormonal regulation, and genetic adaptations. Recent advancements in genetic engineering, nanotechnology, and OMICs approaches have further enhanced our understanding of plant responses to HM stress, paving the way for innovative remediation strategies. This review explores the multifaceted impact of HMs on plant physiology and highlights adaptive responses that contribute to HM tolerance and stress mitigation.

Introduction: Laurus nobilis (bay laurel) is a widely used plant known for its culinary, cosmetic, therapeutic, and pharmacological properties. Its leaves are particularly valued due to their rich content of bioactive compounds, such as essential oils, phenolic substances, flavonoids, and alkaloids. This review aimed to provide a comprehensive overview of the botanical characteristics, chemical composition, and therapeutic and industrial applications of these compounds. Methods: An extensive literature review was conducted using scientific databases to collect and analyze published studies on the botanical traits, chemical constituents, traditional uses, pharmacological activities, and industrial applications of L. nobilis leaves. Results: The analysis revealed that bay leaves contain a variety of bioactive components, notably essential oils, phenolics, flavonoids, and alkaloids. These compounds exhibit significant pharmacological properties, including anti-inflammatory, antimicrobial, antioxidant, and anticancer activities, as supported by various in vitro and in vivo studies. Discussion: The findings underscore the therapeutic relevance of L. nobilis leaves, aligning with traditional medicinal practices and modern pharmacological research. However, limitations exist in terms of standardized extraction methods and clinical trials, which must be addressed to validate and optimize their therapeutic use. Conclusion: Laurus nobilis leaves are a promising natural source of pharmacologically active compounds. Their diverse applications across traditional medicine, modern pharmacology, and industrial sectors highlight their continuing relevance and potential for broader utilization.